#### Check for updates

#### **OPEN ACCESS**

EDITED BY Karina Felipe, Federal University of Paraná, Brazil

#### REVIEWED BY

José Vargas, Federal University of Paraná, Brazil Hongliang Huang, Guangdong Pharmaceutical University, China

\*CORRESPONDENCE Linglin Zhang, ⊠ zhangll363@126.com Xiuli Wang, ⊠ wangxiuli\_1400023@tongji.edu.cn

<sup>†</sup>These authors have contributed equally to this work

#### SPECIALTY SECTION This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology

RECEIVED 02 December 2022 ACCEPTED 07 March 2023 PUBLISHED 17 March 2023

#### CITATION

Zeng Q, Liu J, Yan Y, Zhang G, Wang P, Zhang H, Liu X, Zhang L and Wang X (2023), Modified 5-aminolevulinic acid photodynamic therapy suppresses cutaneous squamous cell carcinoma through blocking Akt/mTOR-mediated autophagic flux. *Front. Pharmacol.* 14:1114678.

doi: 10.3389/fphar.2023.1114678

#### COPYRIGHT

© 2023 Zeng, Liu, Yan, Zhang, Wang, Zhang, Liu, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Modified 5-aminolevulinic acid photodynamic therapy suppresses cutaneous squamous cell carcinoma through blocking Akt/ mTOR-mediated autophagic flux

Qingyu Zeng<sup>†</sup>, Jia Liu<sup>†</sup>, Yu Yan, Guolong Zhang, Periru Wang, Haiyan Zhang, Xiaojing Liu, Linglin Zhang\* and Xiuli Wang\*

School of Medicine, Shanghai Skin Disease Hospital, Institute of Photomedicine, Tongji University, Shanghai, China

**Background:** We previously found that modified 5-aminolevulinic acid photodynamic therapy (M-PDT) is painless and effective in cutaneous squamous cell carcinoma (cSCC) treatment, however, the regulatory mechanism of M-PDT in cSCC is still unclear.

**Objective:** To clarify the effect and relevant regulatory mechanism of M-PDT in cSCC.

**Methods:** The cSCC apoptosis was examined by flow cytometry, TUNEL staining and Cleaved-caspase-3 immunofluorescence, respectively. The autophagyrelated characterization was detected by monodansylcadaverine (MDC) staining, transmission electron microscopy (TEM), GFP-LC3B autophagic vacuoles localization and mRFP-EGFP tandem fluorescence-tagged LC3B construct, respectively. The expression of autophagy-related proteins and Akt/ mTOR signaling molecules were examined by Western blot. ROS generation was measured by DCFH-DA probe.

**Results:** We found that M-PDT induced cSCC apoptosis in a dose-dependent manner, and this result was related to autophagic flux blockage. The phenomenon is confirmed by the results that M-PDT could induce autophagosomes accumulation and upregulate LC3-II and p62 expression. M-PDT elevated co-localization of RFP and GFP tandem-tagged LC3B puncta in cSCC cell, reflecting autophagic flux blockage, and this was confirmed by transmission electron microscopy. Furthermore, we noticed that M-PDT induced accumulated autophagosomes-dependent apoptosis *via* targeting ROS-mediated Akt/mTOR signaling. Suppression of Akt potentiated M-PDT-induced upregulation of LC3-II and p62 levels, whereas Akt activation and ROS inhibition rendered resistance to these events. In addition, we observed that lysosomal dysfunction was involved in M-PDT-triggered accumulated autophagosomes-dependent cSCC apoptosis.

**Conclusion:** Our data demonstrates that M-PDT inhibits cSCC through blocking Akt/mTOR-mediated autophagic flux.

#### KEYWORDS

M-PDT, cSCC, autophagic flux, ROS, AKT/mTOR signaling

# **1** Introduction

cSCC is a common cutaneous malignant tumor worldwide (Hedberg et al., 2022). Even though cSCC is reported only 5% metastasis and has long-term survival after treatment, the aging and growing population has led to an increasing incidence and mortality rate (Shalhout et al., 2022).

5-aminolevulinic acid photodynamic therapy (ALA-PDT) is based on photosensitizer, light source and oxygen to generate cytotoxic effects on targeted position (Zeng et al., 2022a). ALA-PDT is extensively applied in actinic keratosis (AK), Bowen disease (BD), superficial skin SCC, and other cancerous and precancerous skin diseases (Skaria, 2014). Yet we observed that there is apparent pain in conventional ALA-PDT treatment in clinical, which make patients suspend treatment (Arits et al., 2010; Wang et al., 2017). The pain is a key factor limiting efficacy during ALA-PDT. We previously modified conventional ALA-PDT by reducing the ALA incubation time, and increasing the light dose, then we found that this modified ALA-PDT (M-PDT) not only reduced pain but also had acceptable therapeutic effect in severe acne vulgaris (Zhang et al., 2021), condylomata acuminata (Zhang et al., 2020) and cSCC(Liu et al., 2021; Zeng et al., 2022c). However, the molecular mechanism of M-PDT in cSCC remains unclear.

Autophagy is a conserved degradation system in cells which contains a series of procedures such as double membrane formation and elongation, autophagosomes maturation and fusion with the lysosome (Feng et al., 2015; Zhang et al., 2019a). LC3 is a classic marker of autophagy. LC3 contains two molecular forms, the unconjugated form LC3-I and the conjugated form LC3-II which binds to autophagosomes and associates with the number of autophagosomes (Kabeya et al., 2000; Feng et al., 2015). Therefore, the LC3-II protein level is widely used as a biochemical indicator for assessing the state of autophagy. In addition, autophagy adaptor p62 protein could bind to LC3 and ubiquitinated substrates, and p62 is degraded along with cargo in autophagosomes. The degraded p62 protein level reflects the enhancement of autophagy flux, therefore when autophagy flux is blocked, the p62 protein level accumulates (Zhang et al., 2019a). Thus, p62 protein level is important to evaluate the status of autophagic flux (Sharifi et al., 2015). Several studies have reported that the induction of autophagy commonly occurs after PDT (Martins et al., 2020). However, whether the induced autophagy is beneficial during the PDT treatment seems to be controversial including in ALA-PDT. For example, Liu et al. reported that ALA-PDT induces superoxide anion-dependent autophagic cell death in keloids (Liu et al.,



#### FIGURE 1

M-PDT induces cSCC cell viability suppression (A) The percentages of live and apoptotic cells were measured by FACS using annexin-V-FITC/PI staining. (B) Live cells and apoptotic cells in (A) were calculated. (C) TUNEL staining of cSCC cells. (D) After 24 h of M-PDT treatment, immunofluorescence of Cleaved-caspase 3 was detected. The light dose of M-PDT was 54 J/cm<sup>2</sup> for A431 cells, and 21.6 J/cm<sup>2</sup> for SCL-1 cells (C, D). \*p < 0.05, \*\*p < 0.01, difference vs. control group; the scale bar (C, D) is 100 µm. n = 3.



M-PDT induces autophagosomes accumulation and upregulation of LC3-II and p62 expression in cSCC cells (A) The cSCC cells were labeled using MDC staining, the scale bar is 100  $\mu$ m. (B, C) Representative GFP-LC3B fluorescence images (B) and quantified number for GFP-LC3B puncta (C) in cSCC cells, the scale bar is 10  $\mu$ m. (D) Western blot for indicated antibodies. GAPDH is a loading control. Similar results were observed in three independent experiments. (E) The relative densities for LC3-II, p62, and Cleaved-PARP were semi-quantified. \*p < 0.05, \*\*p < 0.01, difference vs. control group. n = 3.

2019), while Zeng et al. (2021) found that autophagy plays a role in promoting survival and inhibiting apoptosis in ALA-PDT treated secondary hyperparathyroidism primary cells. And so far, there is no research on the relationship between M-PDT and autophagy.

In this work, the data showed that M-PDT blocks autophagic flux, leading to autophagosomes-dependent cSCC apoptosis. M-PDT triggers autophagosomes-dependent cSCC cell death by ROS-mediated inhibition of Akt/mTOR signaling pathway. Pharmacological regulation of ROS and Akt could affect M-PDTinduced LC3-II and p62 expression. In addition, we detected that lysosomal dysfunction is involved in M-PDT-induced accumulated autophagosomes-dependent cSCC apoptosis. Our work broaden the molecular mechanism involved in the treatment of M-PDT for cSCC.

# 2 Materials and methods

#### 2.1 Materials

N-acetyl-L-cysteine (NAC), Chloroquine diphosphate (CQ), MDC, MK2206, SC79, DCFH-DA probe were obtained from MedChemExpress. 5-Aminolevulinic acid (ALA) was purchased from Sigma.

# 2.2 Cell lines

A431 (ATCC) and SCL-1 (Daixuan Biotech) cSCC cell lines were cultured in DMEM (HyClone) supplemented with 10% FBS (Yeasen) and 100 U/mL penicillin/streptomycin (Yeasen).



#### 2.3 Cell viability assay

According to the protocol of manufacturer, 1,000 cells per well were seeded in 96-well plates. After 24 h culture, each well was added 10  $\mu$ L CCK8 solution (Yeasen) and incubated for 1 h, then cell viability was detected by the microplate reader at 450 nm absorbance.

#### 2.4 M-PDT treatment

M-PDT treatment was applied following our published methods (Liu et al., 2021). A431 cells were incubated with ALA (1 mM) in serum-free medium away from light for 1 h at 37°C, then exposed to a red LED light (633 nm) at 15 mW/cm<sup>2</sup> for 30, 45 and 60 min, the total light dose was 27, 40.5 and 54 J/cm<sup>2</sup> respectively. As for SCL-1 cells, the illumination time was 20, 22 and 24 min, so the PDT light dose was 18, 19.8 and 21.6 J/cm<sup>2</sup> respectively.

# 2.5 ROS detection

Before M-PDT irradiation, DCFH-DA probe was added into cell medium for 20 min, and ROS production was observed by an inverted fluorescence microscope.

#### 2.6 MDC-labeled autophagic vacuoles

Cells of  $5 \times 10^5$  per well were seeded in 6-well plate. After different treatments, the cells were exposed to MDC (0.05 mM, 10 min), and washed by PBS, then MDC-marked autophagic vacuoles were detected by an inverted fluorescence microscope.

#### 2.7 GFP-LC3B and mRFP-EGFP-LC3B assay

GFP-LC3B and mRFP-EGFP-LC3B lentivirus were purchased from OBiO Technology. After different treatments, cells were fixed with 2% formaldehyde (10 min, room temperature). Autophagosome structure formation was observed by LC3B puncta calculation. Autophagosome maturation was estimated by yellow (accumulation of autophagosomes) and red (autolysosomes) fluorescence structures in cells.

#### 2.8 Western blot assay

Western blot analysis was applied as described previously (Zeng et al., 2022b). The following antibodies were used: p-mTOR (Ser2448), mTOR, p-Akt (Ser473), Akt, p-S6K1 (Thr389), S6K1,



p-4E-BP1(Thr70), 4E-BP1, p-ULK1 (Ser757), ULK1, Cleaved-PARP, SQSTM1/p62, CTSD, GAPDH, LC3B (Cell Signaling Technology).

#### 2.9 Statistical analysis

Data were expressed as the mean value  $\pm$  standard error (mean  $\pm$  SE). Student's t-test for non-paired replicates was used to identify statistically significant differences between treatment means. Group variability and interaction were compared using one-way or two-way analysis of variance followed by Bonferroni's post-test to compare replicate means. p < 0.05 was considered statistically significant.

# **3** Results

# 3.1 M-PDT induces cSCC cell viability suppression

A431 and SCL-1 cells were chosen to study how M-PDT inhibits cSCC cells. We first evaluated apoptosis by Annexin-V-FITC/PI staining. As shown in Figures 1A, B, M-PDT increased the number of apoptotic cells (Q2 and Q3) and decreased the relative number of live cells (Q4) in a concentration-dependent manner. Subsequently,

M-PDT significantly elevated the positive cells number of TUNEL (Figure 1C). We next detected the expression of Cleaved caspase-3 and Cleaved PARP in A431 and SCL-1 cells. The immunofluorescence data indicated that M-PDT induced obvious cleavages of caspase-3 in the cSCC cells (Figure 1D). Western blot results in Figures 2D, E revealed that M-PDT increased cleavages of PARP in a concentration-dependent manner in the cSCC cells. Viewed together, the findings clearly demonstrate that M-PDT induces cSCC cell viability suppression.

#### 3.2 M-PDT induces autophagosomes accumulation and upregulation of LC3-II and p62 expression in cSCC cells

Several studies have reported that autophagic dysfunction may result in apoptosis (Moscat and Diaz-Meco, 2009; Das et al., 2021). Here we observed that M-PDT significantly increased the accumulation of MDC, a specific autophagic vacuoles marker (Dong et al., 2019) in cSCC cells (Figure 2A). We also confirmed that the LC3-II and p62 protein levels were elevated by M-PDT in a concentration-dependent manner in cSCC cells (Figures 2D, E). To confirm the findings, A431 and SCL-1 cells were infected with Ad-GFP-LC3B, subsequently treated with M-PDT, the number of LC3B puncta was profoundly upregulated compared with control group (Figures 2B, C). The above findings indicate that M-PDT induces



autophagosomes accumulation and concomitantly increases protein expression of LC3-II and p62 in cSCC cells, implying that M-PDT could hinder autophagic flux, contributing to subsequent cSCC cell viability suppression.

# 3.3 M-PDT hinders autophagic flux leading to autophagosomes-dependent cSCC cell viability suppression

Autophagosome accumulation-induced autophagic flux blockage has been responsible for cell death (Qiu et al., 2014; Yi et al., 2018). Thus, we wanted to know whether M-PDT-induced autophagosome accumulation also impairs autophagic flux and leading to cSCC cell viability suppression. Examination of intracellular structures using TEM demonstrated that M-PDT obviously increased the number of autophagic vacuoles in A431 and SCL-1 cells (Figures 3A, B). Moreover, we measured autophagic flux in A431 and SCL-1 cells expressing mRFP-EGFP tandem fluorescence-tagged LC3B construct. As shown in Figures 3C, D, the cells in the control group showed only slight red-fluorescence structures (autolysosomes), while the cells in the M-PDT-treated groups showed obvious yellow-fluorescence structures (autophagosomes), which exhibits autophagic flux was blocked. The above data support the concept that M-PDT blocks autophagic flux in cSCC cells.

Next, cSCC cells were pretreated with/without CQ (5  $\mu$ M) for 1 h before M-PDT. CQ could suppress the fusion of autophagosomes and lysosomes. As shown in Figures 4A, B, CQ obviously potentiated the M-PDT-upregulated LC3-II, p62, and Cleaved-PARP protein levels. Furthermore, CCK8 (Figure 4C) results demonstrated that CQ potentiated the inhibition of



M-PDT on cell viability. Collectively, the data suggested that M-PDT hinders autophagic flux contributing to autophagosomesdependent cSCC cell viability suppression.

#### 3.4 M-PDT triggers autophagosomesdependent cSCC cell viability inhibition through ROS-mediated inhibition of Akt/ mTOR pathway

It is known that Akt/mTOR signaling pathway plays an essential role in autophagy regulation (Munson and Ganley, 2015). Therefore, we wondered whether Akt/mTOR pathway is involved in M-PDTmediated autophagy in cSCC cells. The results in Figures 5A, B showed that M-PDT concentration-dependently suppresses the phosphorylation of Akt, the phosphorylation of mTOR, the phosphorylation of S6K1 and the phosphorylation of 4EBP1 and 4EBP1 expression in cSCC cells, indicating that M-PDT indeed inhibits the Akt/mTOR pathway. The ULK1 is an important regulator in autophagy initiation and mTORC1 induces ULK1 inactivation by phosphorylating ULK1 at Ser757 site, thereby suppressing autophagy (Kim et al., 2011). As observed in Figures 5C, D, we found M-PDT concentration-dependently inhibited ULK1 phosphorylation levels at Ser757 (inactive ULK1 form), which is coincide with Akt/mTOR inhibition (Figures 5A, B).

ROS production is essential for the function of M-PDT (Zeng et al., 2022c). We wanted to know whether M-PDT-induced autophagy is ROS-dependent. ROS generation was detected by DCFH-DA probe in Figure 6A. M-PDT could promote ROS generation of cSCC cells. And NAC (10 µM, pretreatment for 1 h) could significantly inhibit M-PDT-elevated LC3-II and p62 and activate M-PDT-inhibited phosphorylation of Akt in cSCC cells (Figures 6B, C). These results reflect that M-PDT triggers autophagosomes-dependent cSCC cell viability inhibition via ROS-dependent inhibition of Akt/mTOR pathway in cSCC cells. CTSD (Cathepsin D) is a specific indicator of lysosomes dysfunction and CTSD is considered as an essential factor for lysosomal proteolytic activity (Di et al., 2021; Hossain et al., 2021). We found that M-PDT obviously decreased the expression of CTSD, while NAC could not rescue M-PDT-suppressed expression of CTSD in A431 and SCL-1 cells (Figures 6B, C). The results



imply that M-PDT could induce lysosomal dysfunction in a ROSindependent manner.

#### 3.5 Pharmacological regulation of Akt affects M-PDT-induced accumulated autophagosomes-dependent cSCC cell viability suppression

Studies have shown that Akt is an important regulator of autophagic flux as well as cell death (Rodriguez-Hernandez et al., 2018; Dong et al., 2019). A431 and SCL-1 cells were pretreated with or without Akt inhibitor MK2206 (500 nM) for 1 h, and then treated with M-PDT. We found that pretreatment with MK2206 obviously enhanced M-PDT-induced LC3-II, p62 protein levels (Figures 7A, B). In addition, MK2206 also potentiated M-PDT's inhibition of cell viability in cSCC cells (Figure 7C). To verify the above findings, an Akt agonist, SC79 was employed. As expected, SC79 (5 µM, pretreatment for 1 h) dramatically attenuated M-PDT-induced increase of LC3-II, p62 levels (Figures 7D, E). Consistently, we also observed that SC79 partially prevented M-PDT's inhibition of cell viability (Figure 7F). Collectively, these data demonstrate that pharmacological regulation of Akt affects M-PDT-induced accumulated autophagosomes-dependent cSCC cell viability suppression.

#### 4 Discussion

We previously clarified that M-PDT is painless and effective in cSCC treatment (Liu et al., 2021; Zeng et al., 2022c), but the underlying inhibitory mechanism remains unclear. The relationship between cell death and autophagy has been widely reported (Gao et al., 2020). Even though the subcellular localization and thus the initial targets for photodamage during PDT protocols vary, the induction of autophagy always occurs, independent of the photosensitizer (PS) used (Reiners et al., 2010). The effect of autophagy on the curative outcome of PDT seems to depend on the type of PS, the cell type, the applied light dose, and its concentration (Garg et al., 2015). For example, Shao et al. (2022) reported that the role of Curcumin-PDT-induced autophagy in the regulation of EMT was found to be a promoting effect in lung cancer. Luo et al. (2021) reported that suppression of autophagy elevates apoptosis induced by Ce6-PDT in colon cancer. However, Hyo et al. reported that Pheophorbide a-mediated PDT induces autophagic apoptosis in human skin cancer cells (Yoon et al., 2014). Here, whether the induced autophagy is beneficial during the PDT treatment seems to be controversial.

Our study focused on autophagy involved in the treatment of M-PDT for cSCC. Zeng et al. (2021) reported that CQ enhanced apoptosis induced by ALA-PDT in secondary hyperparathyroidism primary cells. Li et al. found that blockage of autophagy could



upregulate the apoptosis rate of HR-HPV-infected HeLa cells after ALA-PDT (Deng et al., 2021). However, Ji et al. (2010) found that ALA-PDT could induce autophagic cell death *via* AMPK and the autophagy inhibitor 3-MA elevated the survival rate of PC12 cell in a dose-dependent manner after ALA-PDT. There is few evidence about the association between ALA-PDT with autophagy in cSCC. Zhang et al. (2019b) reported that 3-MA combined with ALA-PDT could inhibit the proliferation of A431 and A375 cells. Here, we reported that M-PDT suppresses cSCC through blocking Akt/mTOR-mediated autophagic flux. CQ potentiated the inhibition of M-PDT in cSCC. Based on current literatures, we speculate that the differences may be related to the different applied light dose and ALA incubation time, these conditions are exactly the distinctions between traditional ALA-PDT and M-PDT.

Autophagy is a double-edged sword for the cell physiological function (Zhang et al., 2016). If autophagosomes can not to fuse with lysosomes, accumulated autophagosome will block autophagic flux and induce cell death (Button and Luo, 2017; Dong et al., 2019). Due to its characteristic of binding to LC3, the expression level of p62 is an important indicator of autophagic flux (Mizushima et al., 2010). In this study, we showed that M-PDT-induced cSCC cell viability suppression was associated with increase of autophagosomes. Western blot analysis revealed that both LC3-II and p62 were elevated in M-PDT group (Figure 2D). These data suggested that M-PDT triggered autophagic flux blockage. Further evidence was obtained when autophagic flux was detected using mRFP-EGFP tandem fluorescence-tagged LC3 construct in Figure 3. Thus, our results suggest that M-PDT could hinder the fusion of autophagosomes with lysosomes and block autophagic flux in cSCC cells.

Akt/mTOR signaling is a key pathway in regulating autophagy as well as cell viability (Bruntz et al., 2014; Rodriguez-Hernandez et al., 2018). We observed that M-PDT inhibits ROS-mediated Akt/ mTOR signaling and hinders autophagic flux, which promotes cSCC cell viability inhibition. Inhibition of Akt with MK2206 strengthened M-PDT-induced upregulation of LC3-II and p62 levels, whereas activate Akt with SC79 rendered resistance to the events. Further experiment elucidated that M-PDT inactivates Akt via ROS production. The lysosome is unique organelle to degrade cargos in autophagy, thence lysosomes dysfunction exhibits serious autophagic flux impairment (Qiu et al., 2014). Lysosomes require a full range of proteases to carry out their function. CTSD is an important aspartic protease in the lysosomes (Hossain et al., 2021). Previous study has indicated that CTSD activity change is a specific indicator of lysosomes dysfunction (Ashtari et al., 2016; Schultz et al., 2016). We also found that M-PDT could affect the protein levels of CTSD, this means that the function of the lysosome is also impaired.

In summary, we demonstrated that M-PDT inactivates ROSmediated Akt/mTOR pathway, which blocks autophagic flux, leading to accumulated autophagosomes-dependent cSCC cell viability suppression. Our results unveil that M-PDT provides a potential solution for the treatment of cSCC and inhibition of autophagy could improve the curative effect of M-PDT.

## 5 Conclusion

We have shown that M-PDT inactivates ROS-mediated Akt/ mTOR signaling, which blocks autophagic flux, leading to autophagosomes accumulation. Furthermore, the accumulated autophagosomes induce cSCC cell viability inhibition (Figure 8). In addition, M-PDT could induce lysosomal dysfunction in a ROS- independent manner. Our results underline that suppression of autophagic flux is a promising combination with M-PDT against cSCC.

#### Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

#### Ethics statement

The animal study was reviewed and approved by the Institutional Research Medical Ethics Committee approved this study from Shanghai Skin diseases hospital.

#### Author contributions

JL performed the data acquisition. QZ wrote the manuscript. The work conceptualization is by QZ and XW. GZ and YY performed the analysis job. PW, XL, and HZ helped with the experiments. XW and LZ revised the manuscript. All authors read and approved the final manuscript.

# References

Arits, A. H., van de Weert, M. M., Nelemans, P. J., and Kelleners-Smeets, N. W. (2010). Pain during topical photodynamic therapy: Uncomfortable and unpredictable. *J. Eur. Acad. Dermatol Venereol.* 24, 1452–1457. doi:10.1111/j.1468-3083.2010.03670.x

Ashtari, N., Jiao, X., Rahimi-Balaei, M., Amiri, S., Mehr, S. E., Yeganeh, B., et al. (2016). Lysosomal acid phosphatase biosynthesis and dysfunction: A mini review focused on lysosomal enzyme dysfunction in brain. *Curr. Mol. Med.* 16, 439–446. doi:10.2174/1566524016666160429115834

Bruntz, R. C., Taylor, H. E., Lindsley, C. W., and Brown, H. A. (2014). Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells. *J. Biol. Chem.* 289, 600–616. doi:10.1074/jbc.M113.532978

Button, R. W., and Luo, S. (2017). The formation of autophagosomes during lysosomal defect: A new source of cytotoxicity. *Autophagy* 13, 1797–1798. doi:10. 1080/15548627.2017.1358850

Das, S., Shukla, N., Singh, S. S., Kushwaha, S., and Shrivastava, R. (2021). Mechanism of interaction between autophagy and apoptosis in cancer. *Apoptosis* 26, 512–533. doi:10.1007/s10495-021-01687-9

Deng, Z., Chen, M., Liu, Y., Xu, S., Ouyang, Y., Shi, W., et al. (2021). A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea. *EMBO Mol. Med.* 13, e13560. doi:10.15252/emmm.202013560

Di, Y. Q., Han, X. L., Kang, X. L., Wang, D., Chen, C. H., Wang, J. X., et al. (2021). Autophagy triggers CTSD (cathepsin D) maturation and localization inside cells to promote apoptosis. *Autophagy* 17, 1170–1192. doi:10.1080/15548627.2020.1752497

Dong, X., Zhao, R., Li, Y., Yu, Q., Chen, X., Hu, X., et al. (2019). Maduramicin inactivation of Akt impairs autophagic flux leading to accumulated autophagosomesdependent apoptosis in skeletal myoblast cells. *Int. J. Biochem. Cell Biol.* 114, 105573. doi:10.1016/j.biocel.2019.105573

Feng, Y., Yao, Z., and Klionsky, D. J. (2015). How to control self-digestion: Transcriptional, post-transcriptional, and post-translational regulation of autophagy. *Trends Cell Biol.* 25, 354–363. doi:10.1016/j.tcb.2015.02.002

Gao, L., Loveless, J., Shay, C., and Teng, Y. (2020). Targeting ROS-mediated crosstalk between autophagy and apoptosis in cancer. *Adv. Exp. Med. Biol.* 1260, 1–12. doi:10. 1007/978-3-030-42667-5\_1

Garg, A. D., Maes, H., Romano, E., and Agostinis, P. (2015). Autophagy, a major adaptation pathway shaping cancer cell death and anticancer immunity responses following photodynamic therapy. *Photochem Photobiol. Sci.* 14, 1410–1424. doi:10.1039/c4pp00466c

Hedberg, M. L., Berry, C. T., Moshiri, A. S., Xiang, Y., Yeh, C. J., Attilasoy, C., et al. (2022). Molecular mechanisms of cutaneous squamous cell carcinoma. *Int. J. Mol. Sci.* 23, 3478. doi:10.3390/ijms23073478

## Funding

This work was supported by the National Natural Science Foundation of China (Nos. 82073013, 81903241). This work was supported by the Shanghai Natural Science Foundation (No. 21ZR1457100).

#### Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

#### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Hossain, M. I., Marcus, J. M., Lee, J. H., Garcia, P. L., Singh, V., Shacka, J. J., et al. (2021). Restoration of CTSD (cathepsin D) and lysosomal function in stroke is neuroprotective. *Autophagy* 17, 1330–1348. doi:10.1080/15548627.2020.1761219

Ji, H. T., Chien, L. T., Lin, Y. H., Chien, H. F., and Chen, C. T. (2010). 5-ALA mediated photodynamic therapy induces autophagic cell death via AMP-activated protein kinase. *Mol. Cancer* 9, 91. doi:10.1186/1476-4598-9-91

Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., et al. (2000). LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. *EMBO J.* 19, 5720–5728. doi:10.1093/emboj/19.21.5720

Kim, J., Kundu, M., Viollet, B., and Guan, K. L. (2011). AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. *Nat. Cell Biol.* 13, 132–141. doi:10. 1038/ncb2152

Liu, J., Yan, G., Chen, Q., Zeng, Q., and Wang, X. (2021). Modified 5-aminolevulinic acid photodynamic therapy (M-PDT) inhibits cutaneous squamous cell carcinoma cell proliferation via targeting PP2A/PP5-mediated MAPK signaling pathway. *Int. J. Biochem. Cell Biol.* 137, 106036. doi:10.1016/j.biocel.2021.106036

Liu, T., Ma, X., Ouyang, T., Chen, H., Xiao, Y., Huang, Y., et al. (2019). Efficacy of 5aminolevulinic acid-based photodynamic therapy against keloid compromised by downregulation of SIRT1-SIRT3-SOD2-mROS dependent autophagy pathway. *Redox Biol.* 20, 195–203. doi:10.1016/j.redox.2018.10.011

Luo, M., Li, H., Han, D., Yang, K., and Kang, L. (2021). Inhibition of autophagy enhances apoptosis induced by Ce6-photodynamic therapy in human colon cancer cells. *Photodiagnosis Photodyn. Ther.* 36, 102605. doi:10.1016/j.pdpdt.2021.102605

Martins, W. K., Belotto, R., Silva, M. N., Grasso, D., Suriani, M. D., Lavor, T. S., et al. (2020). Autophagy regulation and photodynamic therapy: Insights to improve outcomes of cancer treatment. *Front. Oncol.* 10, 610472. doi:10.3389/fonc.2020.610472

Mizushima, N., Yoshimori, T., and Levine, B. (2010). Methods in mammalian autophagy research. *Cell* 140, 313–326. doi:10.1016/j.cell.2010.01.028

Moscat, J., and Diaz-Meco, M. T. (2009). p62 at the crossroads of autophagy, apoptosis, and cancer. *Cell* 137, 1001–1004. doi:10.1016/j.cell.2009.05.023

Munson, M. J., and Ganley, I. G. (2015). MTOR, PIK3C3, and autophagy: Signaling the beginning from the end. *Autophagy* 11, 2375–2376. doi:10.1080/15548627.2015. 1106668

Qiu, W., Su, M., Xie, F., Ai, J., Ren, Y., Zhang, J., et al. (2014). Tetrandrine blocks autophagic flux and induces apoptosis via energetic impairment in cancer cells. *Cell Death Dis.* 5, e1123. doi:10.1038/cddis.2014.84

Reiners, J. J., Jr., Agostinis, P., Berg, K., Oleinick, N. L., and Kessel, D. (2010). Assessing autophagy in the context of photodynamic therapy. *Autophagy* 6, 7–18. doi:10.4161/auto.6.1.10220

Rodriguez-Hernandez, M. A., Gonzalez, R., de la Rosa, A. J., Gallego, P., Ordonez, R., Navarro-Villaran, E., et al. (2018). Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells. *J. Cell Physiol.* 234, 692–708. doi:10.1002/jcp.26855

Schultz, M. L., Krus, K. L., and Lieberman, A. P. (2016). Lysosome and endoplasmic reticulum quality control pathways in Niemann-Pick type C disease. *Brain Res.* 1649, 181–188. doi:10.1016/j.brainres.2016.03.035

Shalhout, S. Z., Kaufman, H. L., Emerick, K. S., and Miller, D. M. (2022). Immunotherapy for nonmelanoma skin cancer: Facts and hopes. *Clin. Cancer Res.* 28, 2211–2220. doi:10.1158/1078-0432.CCR-21-2971

Shao, L., Zhu, Y., Liao, B., Wang, G., Huang, L., Yu, L., et al. (2022). Effects of Curcumin-mediated photodynamic therapy on autophagy and epithelial-mesenchymal transition of lung cancer cells. *Photodiagnosis Photodyn. Ther.* 38, 102849. doi:10.1016/j. pdpdt.2022.102849

Sharifi, M. N., Mowers, E. E., Drake, L. E., and Macleod, K. F. (2015). Measuring autophagy in stressed cells. *Methods Mol. Biol.* 1292, 129–150. doi:10.1007/978-1-4939-2522-3\_10

Skaria, A. M. (2014). European guidelines for topical PDT part 1 JEADV 2013; 27: 536-544. J. Eur. Acad. Dermatol Venereol. 28, 673. doi:10.1111/jdv.12258

Wang, B., Shi, L., Zhang, Y. F., Zhou, Q., Zheng, J., Szeimies, R. M., et al. (2017). Gain with no pain? Pain management in dermatological photodynamic therapy. *Br. J. Dermatol* 177, 656–665. doi:10.1111/bjd.15344

Yi, H., Wang, K., Du, B., He, L., Ho, H., Qiu, M., et al. (2018). Aleuritolic acid impaired autophagic flux and induced apoptosis in hepatocellular carcinoma HepG2 cells. *Molecules* 23, 1338. doi:10.3390/molecules23061338

Yoon, H. E., Oh, S. H., Kim, S. A., Yoon, J. H., and Ahn, S. G. (2014). Pheophorbide a-mediated photodynamic therapy induces autophagy and apoptosis via the activation of MAPKs in human skin cancer cells. *Oncol. Rep.* 31, 137–144. doi:10.3892/or.2013. 2856

Zeng, L., Zou, Q., Huang, P., Xiong, L., Cheng, Y., Chen, Q., et al. (2021). Inhibition of autophagy with Chloroquine enhanced apoptosis induced by 5-aminolevulinic acidphotodynamic therapy in secondary hyperparathyroidism primary cells and organoids. *Biomed. Pharmacother.* 142, 111994. doi:10.1016/j.biopha.2021.111994

Zeng, Q., Yang, J., Ji, J., Wang, P., Zhang, L., Yan, G., et al. (2022a). PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma. *Oncoimmunology* 11, 2061396. doi:10.1080/2162402X.2022.2061396

Zeng, Q., Yang, J., Yan, G., Zhang, L., Wang, P., Zhang, H., et al. (2022b). Celastrol inhibits LL37-induced rosacea by inhibiting Ca<sup>2+</sup>/CaMKII-mTOR-NF- $\kappa$ B activation. Biomed. Pharmacother. 153, 113292. doi:10.1016/j.biopha.2022.113292

Zeng, Q., Zhou, C., Zhang, Y., Yan, G., and Wang, X. (2022c). Modified 5aminolevulinic acid photodynamic therapy reduces pain and improves therapeutic effects in cutaneous squamous cell carcinoma mouse model. *Lasers Surg. Med.* 54, 804–812. doi:10.1002/lsm.23516

Zhang, H., Dong, X., Zhao, R., Zhang, R., Xu, C., Wang, X., et al. (2019a). Cadmium results in accumulation of autophagosomes-dependent apoptosis through activating Akt-impaired autophagic flux in neuronal cells. *Cell Signal* 55, 26–39. doi:10.1016/j. cellsig.2018.12.008

Zhang, H., Shi, L., Zhang, Y., Wang, P., Zhang, G., Cao, Y., et al. (2020). Modified photodynamic therapy to minimize pain in the treatment of condylomata acuminata: A prospective, randomized, self-controlled study. *Photodiagnosis Photodyn. Ther.* 32, 101915. doi:10.1016/j.pdpdt.2020.101915

Zhang, L., Ji, Z., Zhang, J., and Yang, S. (2019b). Photodynamic therapy enhances skin cancer chemotherapy effects through autophagy regulation. *Photodiagnosis Photodyn. Ther.* 28, 159–165. doi:10.1016/j.pdpdt.2019.08.023

Zhang, Y., Zhang, H., Zhang, L., Wang, P., Shi, L., Zhang, G., et al. (2021). Modified 5aminolevulinic acid photodynamic therapy to reduce pain in the treatment of moderate to severe acne vulgaris: A prospective, randomized, split-face study. *J. Am. Acad. Dermatol* 84, 218–220. doi:10.1016/j.jaad.2020.04.146

Zhang, Z., Miah, M., Culbreth, M., and Aschner, M. (2016). Autophagy in neurodegenerative diseases and metal neurotoxicity. *Neurochem. Res.* 41, 409–422. doi:10.1007/s11064-016-1844-x